Academic Journals Database
Disseminating quality controlled scientific knowledge

Pulmonary biology of anti-interleukin 5 antibodies

Author(s): Egan RW | Athwahl D | Chou C-C | Chapman RW | Emtage S | Jenh C-H | Kung TT | Mauser PJ | Murgolo NJ | Bodmer MW

Journal: Memórias do Instituto Oswaldo Cruz
ISSN 0074-0276

Volume: 92;
Issue: suppl.2;
Start page: 69;
Date: 1997;
Original page

Keywords: eosinophils | interleukin-5 | pulmonary inflammation | antibodies | airway hyperresponsiveness

Interleukin 5 (IL-5) is a critical cytokine for the maturation of eosinophil precursors to eosinophils in the bone marrow and those eosinophils then accumulate in the lungs during asthma. We have studied anti IL-5 antibodies on allergic responses in mice, guinea pigs and monkeys and are extending this experiment into humans with a humanized antibody. In a monkey model of pulmonary inflammation and airway hyperreactivity, we found that the TRFK-5 antibody blocked both responses for three months following a single dose of 0.3 mg/kg, i.v. This antibody also blocked lung eosinophilia in mice by inhibiting release from the bone marrow. To facilitate multiple dosing and to reduce immunogenicity in humans, we prepared Sch 55700, a humanized antibody against IL-5. Sch 55700 was also active against lung eosinophilia in allergic monkeys and mice and against pulmonary eosinophilia and airway hyperresponsiveness in guinea pigs. Furthermore, as opposed to steroids, Sch 55700 did not cause immunosuppression in guinea pigs. Studies with this antibody in humans will be critical to establishing the therapeutic potential of IL-5 inhibition.
Save time & money - Smart Internet Solutions      Why do you need a reservation system?